Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.
Wolfram DöhnerStefan D AnkerJaved ButlerFaiez ZannadGerasimos FilippatosJoão Pedro FerreiraAfshin SalsaliCarolyn KaempferMartina BrueckmannStuart J PocockJames L JanuzziMilton PackerPublished in: European heart journal (2022)
Hyperuricaemia is common in HF and is an independent predictor of advanced disease severity and increased mortality. Empagliflozin induced a rapid and sustained reduction of SUA levels and of clinical events related to hyperuricaemia. The benefit of empagliflozin on the primary outcome was observed independently of SUA.
Keyphrases
- uric acid
- heart failure
- metabolic syndrome
- high glucose
- acute heart failure
- clinical trial
- cardiovascular events
- study protocol
- diabetic rats
- drug induced
- left ventricular
- phase ii
- risk factors
- endothelial cells
- atrial fibrillation
- oxidative stress
- randomized controlled trial
- coronary artery disease
- cardiovascular disease